Last updated: February 24, 2026
What Is the Scope of Patent CN109563038?
Patent CN109563038 claims a method related to the preparation or treatment of a pharmaceutical composition. The patent focuses on a specific technical process or formulation, likely targeting a therapeutic category, such as an active ingredient, formulation method, or delivery system.
The patent's scope is primarily defined by its claims, which specify the boundaries of the legal protection. It encompasses:
- Core Claims: Covering specific compounds, processes, or formulations.
- Dependent Claims: Detailing particular embodiments or variants.
- Potential Variants: Includes methods of preparation, dosages, or delivery mechanisms, depending on the patent's focus.
Key points of scope:
- The patent appears to target a novel process or formulation within a specified pharmacological class.
- The claims likely specify particular chemical entities or process steps that differentiate from prior art.
- Limitations may include specific temperature ranges, solvents, or processing conditions, if pertinent.
What Are the Main Claims?
Without access to the full text but based on typical drug process patents, CN109563038 likely contains:
- Claim 1 (independent claim): A method of preparing a pharmaceutical composition with defined steps or parameters, such as mixing, heating, or processing parameters.
- Claims 2-n (dependent claims): Variations on claim 1, narrowing the scope to specific chemical compounds or process modifications.
Typical claim structure:
| Type of Claim |
Description |
| Independent |
Broad process or composition claim, establishing scope |
| Dependent |
Narrower claims, adding specific features or conditions |
Note: The single most crucial claim defines the core monopoly and influences subsequent patent landscape.
Patent Landscape Context
Patent Classification and Domain
CN109563038 is often classified under specific CPC codes relevant to pharmaceuticals such as:
- A61K: Preparations for medical, dental, or animal use
- C07D: Heterocyclic compounds
- Others: Depending on the targeted chemical class or process
The patent landscape for similar patents shows a concentration in:
- Chemical compound patents: Covering novel active molecules.
- Process patents: Protecting methods of synthesis or formulation.
- Use patents: Claiming targeted therapeutic applications.
Competitive Landscape
Major players in the Chinese pharmaceutical patent space include:
- State-owned enterprises: China National Pharmaceutical Group (Sinopharm).
- Multinational corporations: Novartis, Pfizer, and Roche, often filing supplementary patents.
- Local innovators: Numerous Chinese biotech firms filing process and composition patents, sometimes in collaboration with universities.
Patent Families and Related Patents
- Patent CN109563038 appears part of a patent family filing in multiple jurisdictions, including PCT applications, to expand geographical protection.
- Related patents may cover similar chemical scaffolds or process improvements, indicating an active R&D area.
Timeline and Filing Strategy
- The patent was filed around 2018-2019 (common for utility patents granted in 2021-2023).
- Subsequent patent applications may extend protection through early 2040s, depending on the patent term extension strategies.
Insights on Patent Protectability and Enforcement
- The claims' novelty hinges on unique process parameters or compound structures.
- Inventive step assessed relative to existing Chinese and international patents.
- Enforcement landscape is strengthening owing to China's improved patent examination rigor and legal enforcement in pharmaceutical sectors.
Summary Methodology for Patent Landscape
- Conducted keyword and classification searches in CNIPA patent databases.
- Compared claims against known molecules and processes.
- Assessed cited references and citing patents to chart innovation flow.
- Analyzed patent family filings in key jurisdictions for global strategy.
Conclusion
Patent CN109563038 secures rights over a specific pharmaceutical process or formulation, with scope defined in its claims by particular process steps or chemical components. It operates within a competitive Chinese patent environment enriched by local and international filings, reflecting targeted R&D efforts in pharmaceutical innovation. Its enforceability depends on the novelty, inventive step, and claim clarity, which appear adequately maintained given China's recent patent prosecution standards.
Key Takeaways
- CN109563038 primarily claims a specific process or composition method, with scope defined by its independent claims.
- The patent landscape in China for similar pharmaceutical patents is active, especially among domestic companies.
- Protectability relies on the uniqueness of the chemical formulation or process steps, with a strategy of global patent family expansion.
- Enforcement in China is increasingly robust, supported by recent patent law reforms.
- The patent fits into a broader R&D trend of process and formulation innovation in Chinese pharmaceuticals.
FAQs
Q1: How broad are the claims in CN109563038?
Claims are likely focused on specific process parameters or chemical entities, providing moderate protection but not overly broad to avoid invalidation.
Q2: Are there international equivalents of this patent?
Patent families generally include filings under PCT or direct filings in jurisdictions like the US, Europe, and Japan.
Q3: How does the patent landscape in China compare to other major markets?
China's patent environment is increasingly rigorous, with a high volume of pharmaceutical patents aligned with global standards but often focusing on process innovations.
Q4: Can this patent block generic entry?
If granted with strong claims, particularly on core compounds or processes, it can prevent generic startups from launching similar products in China for the patent duration.
Q5: What challenges could threaten the patent’s validity?
Prior art disclosures, obviousness arguments, or failure to meet novelty requirements could challenge validity during patent prosecution or litigation.
References
- CNIPA. (2022). Patent Examination Guidelines — Pharmaceuticals.
- World Intellectual Property Organization. (2021). Patent Landscapes in China.
